In November 2023, Enhanc3D Genomics appointed Dr Hazel Jones as interim CEO and COO. Now she has taken over the Position of CEO officially.

Swiss Seed Biosciences SA and UK-based Cryologyx Ltd have won the SLAS Europe Product Award 2024 for product developments with transformational potential for the sector.

Over the past few years, the Frankfurt Institute of Clinical Cancer Research (IKF) has successfully conducted over 90 clinical studies. Each year, it enrolls approximately 1,500 patients in these trials. European Biotechnology spoke with the founder and director Prof. Dr med. Salah-Eddin Al-Batran.

Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.

The 2023 State of the Union speech saw biotechnology rise as a priority for the European Union. It has been designated as a critical technology for Europe’s economic security. In March 2024, the European Commission presented its biotechnology and biomanufacturing strategy with a clear leadership ambition for Europe’s biotech industries. The Letta Report on the future of the Single Market, published April 2024, proposed a fifth freedom on research and innovation which would directly benefit biotech.

Swiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc.

Sino Biological offers a comprehensive array of recombinant cytokines tailored for cell culture to advance research in tumor immunotherapy, stem cell therapy, drug screening, and regenerative medicine.

London-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round.

Danish industrial biotechnology startup Cellugy raises €4,9m with the ambition to replace petrochemicals in personal care products.

Obesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.